White Paper on the Treatment of Hypertension and Asthma

In recent years, the subfield of endovascular interventions has received a lot of attention with the rapid development of neurointerventions, cardiovascular interventions and cardiac electrophysiology. However, the field of hypertension, which has the largest number of patients in the field of cardiovascular disease, a heavy burden of disease on society, and a huge potential for improvement in disease diagnosis, treatment, and control, has not received the attention it deserves. In fact, in the field of device therapy for several major chronic diseases corresponding to the cardiopulmonary system, such as hypertension, asthma, chronic obstructive pulmonary disease, and early stage tumours of the lungs, China is still in the early stages of development, and so far there is no industry leading enterprise, and there is still a huge market potential yet to be developed. Against this background, on 14 January 2023, CIC Consultants officially released the "China Hypertension and Asthma Intervention Blue Book" (hereinafter referred to as the "Blue Book"), and on 18 January, the Blue Book Interpretation Meeting, hosted by CIC Consultants, was ceremoniously held online.